Home > Insider Trading > Filing (0001209191-20-050463)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1322505	Albireo Pharma Inc.	ALBO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1213040	J. Martha Carter	C/O Albireo Pharma, Inc. 10 Post Office Square, Suite 1000 Boston MA 02109	Chief Regulatory Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-09-11	9,062	$24.48	9,062	No	4	M	Direct
Common Stock	Acquisiton	2020-09-11	938	$29.76	10,000	No	4	M	Direct
Common Stock	Disposition	2020-09-11	10,000	$40.03	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-09-11	9,062	$0.00	9,062	$24.48
Common Stock	Stock Option (right to buy)	Disposition	2020-09-11	938	$0.00	938	$29.76

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,250		2027-08-20	No	4	M	Direct
62,009		2026-11-27	No	4	M	Direct

Footnotes

Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
This option vests and become exercisable in equal installments on the last day of 16 consecutive calendar quarters beginning with September 30, 2017 and ending on June 30, 2021.
This option vested and became exercisable as to 25% of the underlying shares on November 28, 2017 and the remainder vests in equal installments on the last day of the 12 consecutive calendar quarters beginning with March 31, 2018 and ending on December 31, 2020.